Loos, Carolin
Coccia, Margherita http://orcid.org/0000-0003-1947-4735
Didierlaurent, Arnaud M. http://orcid.org/0000-0002-4736-9003
Essaghir, Ahmed
Fallon, Jonathan K.
Lauffenburger, Douglas http://orcid.org/0000-0002-0050-989X
Luedemann, Corinne
Michell, Ashlin
van der Most, Robbert http://orcid.org/0000-0002-3065-6946
Zhu, Alex Lee
Alter, Galit
Burny, Wivine http://orcid.org/0000-0001-8063-4596
Funding for this research was provided by:
GlaxoSmithKline Biologicals SA
Article History
Received: 8 April 2022
Accepted: 27 January 2023
First Online: 8 March 2023
Competing interests
: M.C., A.E., and W.B. are employees of GSK. A.M.D. and R.v.d.M. were employees of GSK at the time of the study. A.M.D., R.v.d.M., M.C., and W.B. hold shares in GSK. A.M.D. and M.C. have patents on AS01 pending. G.A. is co-founder of Seromyx Systems, Inc. and has a patent on Systems Serology Platform pending. M.C., A.M.D., A.E., R.v.d.M., G.A., and W.B. declare no other financial and non-financial relationships and activities. C. Loos, J.K.F., D.L., C. Luedemann, A.M., and A.L.Z. declare no financial and non-financial relationships and activities and no conflicts of interest.